ArticleLaser therapy2017
Evaluation of photodynamic therapy effect along with colistin on pandrug-resistant
Article in Laser therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 12 citations in OpenAlex.
- Antimicrobial Photodynamic Therapy With New Methylene Blue and Its Combined Effect With Antibiotics Against MDR Acinetobacter baumannii.MicrobiologyOpen · 2026Article
- Colistin Resistance: From Laboratory Research to Modern Clinical Management.Antibiotics (Basel, Switzerland) · 2026Review
- Colistin Resistance in Bacteria: Current Updates on Mechanism of Action and Combating Strategies.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2026Review
- Colistin Resistance Mechanism and Management Strategies of Colistin-ResistantPathogens (Basel, Switzerland) · 2024Review
- Colistin Resistance and Management of Drug Resistant Infections.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2022Review
- Factors mediatingCurrent research in microbial sciences · 2022Review
- Considerations and Caveats in Combating ESKAPE Pathogens against Nosocomial Infections.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2020Review
- Photodynamic enhancement of the activity of antibiotics used in urinary tract infections.Lasers in medical science · 2019Article
- Using Colistin as a Trojan Horse: Inactivation of Gram-Negative Bacteria with Chlorophyllin.Antibiotics (Basel, Switzerland) · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsPandrug-resistant MATERIALS AND
methodsPDRAB which was isolated from burn patients was used as a test strain. PDT carried out in which toluidine blue O (TBO) and light-emitting diode (LED) were used as photosensitizer and radiation source, respectively. Then, the effect of PDT plus colistin was evaluated on CoRAB and the colony-forming units of each tested groups calculated. Finally, confirmation of antibacterial activity of combination therapy was carried out using scanning electron microscope.
resultsPDT declined bacterial count in comparing with control group by 83.7% of killing percentage, in other words, less than one log reduction. While PDT in combination with colistin showed high synergetic effect against
conclusionsAccording to our results, PDT alone couldn't eliminate all of the treated bacterial cells. But when combined with colistin, it killed all of the treated bacterial cells in all tested concentrations. Also PDT decreased the minimal inhibitory concentration of colistin against PDRAB by more than 11 fold.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.